Laminin Polymerization and Inherited Disease: Lessons From Genetics by Shaw, Liam et al.
fgene-12-707087 August 6, 2021 Time: 14:55 # 1
MINI REVIEW








Centre National de la Recherche
Scientifique (CNRS), France
Nicolina Cristina Sorrentino,
Telethon Institute of Genetics




†These authors have contributed
equally to this work and share first
authorship
Specialty section:
This article was submitted to
Genetics of Common and Rare
Diseases,
a section of the journal
Frontiers in Genetics
Received: 08 May 2021
Accepted: 13 July 2021
Published: 12 August 2021
Citation:
Shaw L, Sugden CJ and Hamill KJ
(2021) Laminin Polymerization
and Inherited Disease: Lessons From
Genetics. Front. Genet. 12:707087.
doi: 10.3389/fgene.2021.707087
Laminin Polymerization and Inherited
Disease: Lessons From Genetics
Liam Shaw†, Conor J. Sugden† and Kevin J. Hamill*
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The laminins (LM) are a family of basement membranes glycoproteins with essential
structural roles in supporting epithelia, endothelia, nerves and muscle adhesion, and
signaling roles in regulating cell migration, proliferation, stem cell maintenance and
differentiation. Laminins are obligate heterotrimers comprised of α, β and γ chains that
assemble intracellularly. However, extracellularly these heterotrimers then assemble into
higher-order networks via interaction between their laminin N-terminal (LN) domains.
In vitro protein studies have identified assembly kinetics and the structural motifs
involved in binding of adjacent LN domains. The physiological importance of these
interactions has been identified through the study of pathogenic point mutations in LN
domains that lead to syndromic disorders presenting with phenotypes dependent on
which laminin gene is mutated. Genotype-phenotype comparison between knockout
and LN domain missense mutations of the same laminin allows inferences to be drawn
about the roles of laminin network assembly in terms of tissue function. In this review,
we will discuss these comparisons in terms of laminin disorders, and the therapeutic
options that understanding these processes have allowed. We will also discuss recent
findings of non-laminin mediators of laminin network assembly and their implications in
terms of basement membrane structure and function.
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INTRODUCTION
Basement membranes (BMs) are flexible 40–120 nm sheets that separates cells from underlying
connective tissue and regulate important cell behaviors such as cell polarity and migration,
metabolism, and in inducing differentiation (Paulsson, 1992). Most BMs consist of two layers; an
electron-lucent layer, lamina lucida comprised predominantly of laminins (LMs) and nidogens, and
an electron dense layer, lamina densa of type IV collagen (col IV) and perlecan (Paulsson, 1992).
BMs assemble through a multistep process, with the LM network assembling first (Kalb and Engel,
1991; Smyth et al., 1998; Li et al., 2002, 2005; McKee et al., 2007, 2009) via anchoring of the LMs
cell surface receptors (Kalb and Engel, 1991; Smyth et al., 1998; Li et al., 2002, 2005; McKee et al.,
2007, 2009). Anchorage increases local LM concentration, allows polymerization and recruitment
of other components to the LM scaffold.
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THE LAMININS
Laminins are an obligatory feature of every BM. Each LM is an
αβγ heterotrimer comprised of one of five α chains (encoded by
LAMA1-5), one of four α chains (LAMB1-4) and one of three γ
(LAMC1-3) chains (Aumailley et al., 2005; Domogatskaya et al.,
2012; Aumailley, 2013). Use of alternative promoters in LAMA3
gives rise to either the short LMα3A or the longer LMα3B form,
which are functionally and structurally distinct (Ryan et al.,
1994; Ferrigno et al., 1997). Restrictions in heterotrimerization
potential means that only 16 αβγchain combinations are possible
(Paulsson et al., 1985; Engel et al., 1991; Nissinen et al., 1991;
Utani et al., 1994). These are differentially expressed and play
context specific roles. For example, α1β1γ1 (LM111) is essential
for embryonic development and knockout of any of those genes
is not compatible with life, whereas α3Aβ3γ2 (LM332) is highly
expressed in mature epithelial tissues and loss of function leads to
epidermal fragility.
The LM family has arisen by gene duplication and
rearrangement, and common structural motifs are shared
between members (Figure 1A). Archetypal LM chains consists of
a laminin N-terminal domain (LN domain) followed by rod-like
stretches of epidermal growth factor-like repeats (LE domains)
interspersed with globular domains (L4 or LF domains) and
followed by a coiled coil domain (LCC domain) through which
αβγ heterotrimers form (Paulsson et al., 1985; Engel et al.,
1991; Nissinen et al., 1991; Zimmerman and Blanco, 2007). In α
chains, the LCC domain is followed by five LM globular domains
(LG1-5), which harbor the highest affinity cell surface receptor
sites (Timpl et al., 2000). While this architecture holds true for
most LMs, not all chains contain all domains. Importantly, the
α3A, α4, and γ2 chains contain shorter amino terminal arms
lacking LN domain (Aumailley et al., 2005; Hamill et al., 2009).
LN Domains
Laminin N-terminal domain are 252–264 amino acid globular
domains found not only in LMs but also other ECM proteins
including netrins. 14% of all residues in LN domains are
conserved with strict conservation of six key cysteines. There is
72% homology between LMα1 and LMα2, 77% between LMα3B
and LMα5, 72% between LMβ1 and LMβ2, and 64% between
LMγ1 and LMγ3 LN domains. Lowest conservation is between
LMβ3 and the β1 and β2 LN domains (38 and 42%, respectively)
(Garbe et al., 2002).
Laminins interactions have been studied over many
years with important early work establishing a “three-arm”
model; polymerization only occurs when all the constituent
chains contain LN domains (Yurchenco and Cheng, 1994;
Hohenester and Yurchenco, 2013). Moreover, interactions
must be heterotypic, involving an α, β and γ LN domain
(McKee et al., 2007). The assembly process is divided into a
temperature-dependent oligomerization step and a calcium-
dependent polymerization step. In vitro analyses have further
shown that the αβγ ternary node assembly involves rapid but
unstable formation of βγ pairs that are then stabilized through
integration of an αLN domain (Hussain et al., 2011; Figure 1B).
In line with the three-arm model, LMs that lack one or more
LN domain cannot polymerize independently (Hohenester and
Yurchenco, 2013). These include LM332 and LM411, which are
abundantly expressed in many epithelial and endothelial BMs.
For these LMs, alternative methods of interaction with other
LM isoforms may be required for BM assembly. For LM332,
incorporation into skin BM can be partly explained by an
interaction between LM332’s β3LN domain with the LE domain
of α3 in LM311. These LM dimers could then self-associate
into higher order networks (Champliaud et al., 1996; Rousselle
and Beck, 2013). Non-network forming LM BM incorporation
likely also depends on compensatory interactions with other
BM/ECM components, such as the β3LN domain binding of
the NC1 domain of type VII collagen, nidogen binding to
the γ1 LE repeats (Chen et al., 1997; Rousselle et al., 1997;
Rousselle and Beck, 2013).
The crystal structures of α5, β1, γ1 LN domains have
been solved, and these combined with conservation of residues
between chains allows inferences as to which regions are
involved in domain folding and those involved αβγ ternary node
formation (Figure 1C). The crystals revealed a similar overall
structure of an antiparallel β sandwich with 8 β sheets forming
a jelly roll motif held in conformation by cysteines C200 and
C220 (Figure 1D; Hussain et al., 2011; Carafoli et al., 2012).
In the α5LN domain, two conserved motifs Patch 1 and Patch
2 are of particular relevance (Hussain et al., 2011). Patch 1
within the conserved β1-β2-β7-β4-β5 “back face,” consists of
E178, P189, R265, and R267. These residues are blocked by
a glycan attached to N148 (Hussain et al., 2011), suggesting
that Patch 1 plays a structural, non-polymerizing role (Carafoli
et al., 2012). Patch 2 is located across the β6-β3-β8 “front face,”
residues W132 and N168, and the β5-β6 loop, residues P229,
L230, and E231. Patch 2 is not glycosylated nor conserved
with β- or γ-chains but is important for polymerization as
mutation of PLENGE residues in the β5-β6 loop all result in
inhibition of polymerization (Hussain et al., 2011; Carafoli et al.,
2012). The β-sandwiches of β1LN and γ1LN domains have
similar structure with the main differences in peripheral regions
(Carafoli et al., 2012). β1LN contains two particular regions of
functional importance: the βa-βb hairpin and the β7-α4 loop.
The βa-βb hairpin sits at the top of the domain with S80 a key
residue for β-γLN interactions (Purvis and Hohenester, 2012).
One notable difference in γ1LN domain is a calcium binding site
located within a short α-helix and flanked by highly conserved
D106 and T114 (Carafoli et al., 2012). Testing inferences about
residue function is a laborious task but elegant in vitro analysis
using LN domain- fusion proteins have been performed and
improve interpretation of clinical findings, discussed in context
below (McKee et al., 2018).
Laminin N-terminal domains, in addition to polymerization,
are implicated in cell adhesion, neurite outgrowth, perlecan,
heparin and heparan sulfate binding (Nielsen and Yamada, 2001;
Nomizu et al., 2001; Garbe et al., 2002; Kunneken et al., 2004).
The LN domain of LMα1, α2, and α5 can interact with integrins
α1β1, α2β1, and α3β1, and presumed between LMα3b and
integrin α3β1 based on antibody inhibition (Pfaff et al., 1994;
Colognato et al., 1997; Ettner et al., 1998; Kariya et al., 2004;
Hozumi et al., 2012). These interactions are lower affinity than
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FIGURE 1 | (A) Diagrammatic representation of archetypal LM structure. Yellow ovals αLN domains, red = βLN domains and blue = γLN domains. LE, laminin-type
EGF-like repeat; LCC, laminin coiled coil domain; LG, laminin globular domains. (B) Two-step laminin network assembly. Secreted LMs associated with cell surface
receptors, predominantly via their LG domain regions, β− γ LN domain interactions are then facilitated in a reaction with rapid on/off kinetics, then in the propagation
step β− γ interactions are stabilized via incorporation of an α-chain leading to a stable cell-associated network. (C) Sequence alignments of LN domains from
human laminin chains, netrin-1 and netrin-4. Yellow, orange, and gray highlights indicated conserved cysteines, fully conserved residues, or partially conserved
residues. Magenta highlight identifies LENGE region. Red squares indicate pathogenic missense mutations. (D) Crystal structures of LN domains. View of the front
and back face of the β1 chain is shown with features of conserved patches involved in LN-interaction (patch 2) and required for domain folding (patch 1). Amino
acids associated Pierson syndrome mutations are indicated numbered based on LMβ1 with LMβ2 equivalent in parenthesis. Crystal structures derived from Hussain
et al. (2011) and Carafoli et al. (2012) rendered using UCSF chimera (Pettersen et al., 2004). * = conserved residue, : = conservation of residues with strongly similar
properties, . = conservation of residues with weakly similar properties.
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LG domain interactions and likely are involved in localization to
allow polymerization rather than signal propagation.
Laminin LN Domains and Human Genetic
Disease
The importance of LN domains to tissue function becomes
apparent when the variety of LN domains mutations which lead
to human disease are considered. Each affected LM results in
a distinct set of syndromic disorders reflecting isoform-specific
distribution and functions (Table 1).
LAMB2 Mutations (Pierson Syndrome)
Pierson syndrome first described in 1963, is a severe congenital
nephrotic syndrome with eye abnormalities (Pierson et al.,
1963), caused by mutations in LAMB2 (LMβ2). LMβ2 is highly
expressed in the glomerular basement membrane, multiple ocular
structures (lens, retina, and cornea), and neuromuscular synapses
(Hunter et al., 1989; Noakes et al., 1995; Libby et al., 2000;
Bystrom et al., 2006). In addition to the defining features
of congenital nephrotic syndrome that rapidly progresses to
end-stage renal failure, and microcoria, many patients develop
complications of motor delay, speech difficulties, intellectual
disability, and seizures (Bowen et al., 1964). Indeed, the spectrum
of LAMB2-related phenotypes is vast. The severest forms of
the disease are associated with knockout mutations, whereas
the majority of missense and indel mutations cluster to the LN
domain and result in milder forms of the disease (Table 1).
One of the earliest studied LMβ2 LN mutations, R246W, is
characterized by severe end-stage renal disease and microcoria
(McKee et al., 2018). Similarly, R246Q, resulted in severe
glomerular abnormalities and impaired secretion (Chen et al.,
2011). Conservation of this arginine led to predictions that
mutations impair LM polymerization, and in vitro this mutant
polymerize substantially less effectively than the wild type
protein (Zenker et al., 2004). However, R246W also reduced
abundance of LM in BMs, likely due to disturbed protein
processing (Matejas et al., 2010). Together these data indicate
that this arginine has a role in protein folding. A second highly
studied missense mutation, S80R, affects the highly conserved
βa-βb and directly prevents LN–LN domain interactions with
polymerization disrupted in vitro (Matejas et al., 2010; Carafoli
et al., 2012; Purvis and Hohenester, 2012). Again, the importance
of this region was further highlighted by an adjacent V79del
patient (Matejas et al., 2006), presenting with milder symptoms
of atypical diffuse mesangial sclerosis, retinal detachment,
and myopia.
Other β2LN mutations with variable phenotypes include
H147R (Mohney et al., 2011), L139P (Matejas et al., 2010), D167Y
(Kagan et al., 2008), and S179F (Choi et al., 2008). Similar to
R26Q, H147R caused a partial reduction in polymerization ability
in vitro. L139P and D167Y mutations are near each other and are
predicted to affect LN domain folding, and together suggest this
region to be particularly sensitive to changes. L139P interferes
with the hydrophobic core, is associated with a particularly
severe phenotype. In contrast, the D167, and H147 result in
milder phenotypes.
LAMA2 Mutations – (Merosin-Deficient Congenital
Muscular Dystrophy Type 1A)
Mutations affecting α LN domains affect the stabilization step
of ternary node assembly. The best example is merosin-deficient
congenital muscular dystrophy type 1A (MDC1A), caused by
mutations to LAMA2 (LMα2) (Helbling-Leclerc et al., 1995). This
affects LM211 and LM221, the most abundant LMs in skeletal
muscles (Ehrig et al., 1990), peripheral nerves, astrocytes and
pericytes in the brain (Voit et al., 1995).
In LMα2 knockout conditions, MDC1A presents with
disabilities of the proximal and distal limb muscles, with patients
unable to walk more than a few steps unaided (Philpot et al.,
1995; Jones et al., 2001). Weakness in facial muscles result
in reduced sucking and swallowing capabilities, life-threatening
problems can arise from failure of the respiratory muscles
(Mendell et al., 2006), and cases with intellectual disability and
epilepsy have been reported (Philpot et al., 1995; Muntoni and
Voit, 2004; Mendell et al., 2006). In knockout situations, LM411
replaces LM211 in muscle basement membranes (Ringelmann
et al., 1999). LMα4 lacks an LN domain and is unable to
polymerize, resulting in a weakened BM. LMα4 and LMα2
also differ in their receptor binding interaction repertoire
and affinities (Talts et al., 2000), for example, LMα2 binds
integrin α7β1 whereas LMα4 cannot, and LMα4 has weaker
affinity for α-dystroglycan (Nishiuchi et al., 2006). Comparison
between missense mutations and knockout mutations allows
differentiation between polymerization and receptor-mediated
effects, although these inferences are complicated by not every
affected tissue expressing LM411.
Many mutations have been reported throughout LAMA2’s 65
exons in MDC1A and are cataloged in LAMA2 gene variant
database1 (Oliveira et al., 2018). Again, the LN domain contains
a cluster of missense and in frame deletions (Patton et al.,
2008; Oliveira et al., 2018). For example, a point mutation
in the highly conserved CxxC motif, C79R, led to a milder
form of MDC1A, which affects the myelination of Schwann
cells in spinal roots and the stability of the skeletal muscles
(Patton et al., 2008). This amyelination was not attributed
to a change in abundance or mislocalization, and in vitro
assays confirmed a dramatic effect on LM polymerization
(McKee et al., 2018). Other pathogenic missense variants include
Q167P, Y138H, G284R on the surface of α2 LN domain and
C86Y, W152G, S157F, S277L, S204F, L243P in the interior
(Yurchenco et al., 2018; Table 1). The S204F mutation lies at
one extreme of the phenotypic spectrum, whereby the patient
was misdiagnosed with a peripheral neuropathy, presenting with
mild proximal weakness. Muscle biopsy revealed depletion of
LMα2 in intramuscular nerve, subtly depleted LMα2 expression
in muscle BMs and diffusely upregulated LMα5 expression (Chan
et al., 2014). To the other extreme, Q167P maps to near the
polymerization face, and consistent with this, causes a 60% drop
in in vitro polymerization capability. This leads to ambulatory
muscular dystrophy (McKee et al., 2018). More severe still,
G284R causes proximal weakness, with a loss of functional
gait with age accompanied by frequent falls, and epilepsy. The
1https://www.lovd.nl/LAMA2
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TABLE 1 | Pathogenic LN domain mutations.
Protein Mutation Effect Phenotype References
LMα1 Y265C LN interaction [mouse] Retinal vasculopathy Edwards et al., 2010
LMα2 C79R LM poly/foldc [mouse] mild muscular dystrophy Patton et al., 2008
C86Y foldp MDC1A Oliveira et al., 2018
Y138H LM polyp MDC1A Oliveira et al., 2008
W152G foldp Limb-girdle–type dystrophy Gavassini et al., 2011
S157F foldp MDC1A Geranmayeh et al., 2010
Q167P LM polyc Limb-girdle–type dystrophy Di Blasi et al., 2005
S204F foldp Mild muscular dystrophy, mild proximal weakness Chan et al., 2014
L243P foldp Mild MDC1A Gavassini et al., 2011
S277L foldp MDC1A Beytia Mde et al., 2014
G284R LM polyp limb-girdle–type dystrophy Gavassini et al., 2011
LMα5 R286L LM polyc Focal segmental glomerulosclerosis, hearing loss, craniofacial dysmorphism,
limb development
Jones et al., 2020
LMβ1 E215K LM polyc [fly] heart development defects Hollfelder et al., 2014
V226E [fly] heart development defects Hollfelder et al., 2014
G286R [fly] heart development defects Hollfelder et al., 2014
LMβ2 R246W R246Q LM Secretion/Fold End-stage renal disease, nephrotic proteinuria, diffuse mesangial sclerosis,
focal and segmental glomerulosclerosis, microcoria, lens abnormalities,
nystagmus hypotonia, cognitive defects, muscle delay
Zenker et al., 2004;
Hasselbacher et al., 2006;
Bredrup et al., 2008;
Matejas et al., 2010
V79del LM polyp Retinal detachment, cataracts, progressive vision loss, diffuse mesangial
sclerosis, end-stage renal disease
Matejas et al., 2006
S80R LM polyc Nephrotic proteinuria, atypical diffuse mesangial sclerosis, myopia, retinal
detachment. [mouse S83R] Detrimental on Alport syndrome background
Matejas et al., 2010;
Funk et al., 2018
H147R LM foldp Nephrotic proteinuria, diffuse mesangial sclerosis, proliferative
glomerulonephritis, hypertension, heart failure, microcoria, retinal detachment,
lens abnormalities
Mohney et al., 2011
D167Y LM Secretionp End-stage renal disease, myopia, retinal detachment, severe visual impairment Kagan et al., 2008
L139P LM foldp Diffuse mesangial sclerosis, lens abnormalities, severe visual impairment,
hypotonia, muscle delay, cognitive deficits
Matejas et al., 2010
S179F LM foldp End-stage renal disease, focal and segmented glomerulosclerosis, retinal
detachment, severe visual impairments
Choi et al., 2008
LMβ3 E210K Splicingc + foldp Skin fragility, nail dystrophy, alopecia Mellerio et al., 1998
ppredicted cconfirmed in vitro assays.
mutation effect is yet to be confirmed but predicted to inhibit LM
polymerization (Gavassini et al., 2011).
LAMA5 Mutations (Kidney, Craniofacial, and Limb
Development Syndrome)
LMα5 is almost ubiquitous to all adult BMs. Unsurprisingly,
knockout mice die before birth with a failure in neural tube
closure, and no human knockouts have been reported (Miner
et al., 1998). However, a patient with R286L in LMα5 LN
has been identified. They presented with a complex syndromic
disease characterized by defects in kidney, craniofacial and
limb development (Jones et al., 2020). The affected residue lies
adjacent to the conserved PLENGE sequence required for LM
polymerization (Hussain et al., 2011), and R286L abrogated
in vitro polymerization potential (Jones et al., 2020). We cannot
compare the LN mutation against knockout; however, a patient
with V3140M, in the LG3 domain has been reported (Sampaolo
et al., 2017). Both the LG3 mutation and R286L lead to complex
syndromic disorders with similarity in tissues affected but with
notable differences. Specifically, in the skin V3140M caused
alopecia, lack of eyebrows and body hair, features not present
in the R286L patient. V3140M patients also had retinal rod
degeneration whereas the R286L had hearing loss but no sight
abnormalities. Kidney defects were common to both with R286L
presenting with atypical focal segmental glomerulosclerosis
progressing to end stage kidney disease compared with floating
kidney syndrome in V3140M. Finally, R286L presented with
numerous dysmorphic issues include craniofacial dysmorphism,
syndactyly, and pyloric web.
LAMB3 Mutation (Junctional Epidermolysis Bullosa)
LMβ3 is expressed in most epithelial tissues where it forms part
of LM3a32 and LM3b32 (Matsui et al., 1995; Ferrigno et al.,
1997). The resulting heterotrimers have either one or two LN
domains and are unable to polymerize independently (Yurchenco
and Cheng, 1994; Cheng et al., 1997). One would assume
that LN domain mutations are tolerated for this LM chain.
However, patients were identified where the pathogenic mutation
caused E210K, which gives rise to a phenotype of trauma-
induced blisters, nail dystrophy and alopecia (mild junctional
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epidermolysis bullosa) (McGrath et al., 1995; Mellerio et al., 1998;
Posteraro et al., 2004). In comparison, homozygous knockout of
LMβ3 leads to much more extensive skin blistering complications
and early lethality (Pulkkinen et al., 1994; Kuster et al., 1997;
Ryan et al., 1999; Meng et al., 2003).
Interpretation of the E210K mutation is complicated; the
affected base pair is at a splice junction and in a knock-in mouse
model led to skipping of the out-of-frame, and no detectable
LMβ3 in the skin. However, in humans, miss-splicing has been
reported for some, but not all patients, which can be rescued
by second-site mutations (Pasmooij et al., 2007). Numerous
alternative splice products are produced, including some full-
length transcripts. Modeling of the E210K mutation indicates it
is unlikely to be required for laminin polymerization but also is
not predicted to affect protein folding or secretion (Mittwollen
et al., 2020). The most common in-frame deletion is predicted
to remove several of the central β-strands and disrupt the fold.
Overall, the evidence from these patients does not point toward
a LM polymerization effect but does suggest a role for the
LMβ3 LN domain in protein function. Direct evidence for the
importance of the LMβ3 LN domain has been obtained from
keratinocytes expressing either full-length or LN domain-deleted
LMβ3 and grafted as skin equivalents onto immunodeficient
mice (Sakai et al., 2010). Here, the LN deleted versions displayed
subepidermal blistering, erosions, and prominent granulation
tissue, not associated with reduced LM332 deposition pointing
LN domain roles beyond polymerization.
Non-human LN Domain Mutations
LMα1 is extremely important for developmental processes, with
knockout mice embryonic lethal. However, Y256C mice are
viable with retinal defects of vitreal fibroplasia, vascular tortuosity
and hypervascularization, and abnormalities to the retinal inner
limiting membrane (Edwards et al., 2010). No reduction in LMα1
was noted, and a two-hybrid screen identified the mutation affects
LN–LN interaction. Random mutagenesis in Drosophila has
identified three LN domain mutations in LMβ1 that led to heart
developmental defects, E215K, V226E, and G286R (Hollfelder
et al., 2014). Of these, E215K was tested in in vitro assays and
reduced polymerization (McKee et al., 2018).
LM Network Regulators: Netrin-4 and
LaNt α31
The netrins family of proteins are structurally and ancestrally
related to LMs (Tessier-Lavigne and Goodman, 1996; Fahey
and Degnan, 2012). Each netrin comprises a LN domain
and stretch of LE repeats followed by a unique C-terminal
region (Kappler et al., 2000; Yurchenco and Wadsworth,
2004). The LN domains of most netrins have diverged that
they do not influence LM network assembly. However, for
netrin-4 the situation is dramatically different where the
β-type LN domain of netrin-4 can potently disrupt LM
networks (Schneiders et al., 2007; Reuten et al., 2016, 2021).
The physiological implications of this ability are beginning to
be appreciated; recent work has demonstrated that netrin-4
levels are a key determinant of basement membrane stiffness
with knock-on effects to cell behavior and tumor metastasis
(Reuten et al., 2016, 2021).
Whereas netrins have evolved as independent genes,
alternative splicing from LM genes or proteolytic processing
of LM proteins leads to generation of LN domain containing
fragments (Kariya et al., 2004; Hamill et al., 2009; Horejs et al.,
2014). These fragments contain “perfect” LN domains that
are likely to compete for binding sites (with reduced potency
compared with netrin-4). One LAMA3-derived alternative splice
isoform, Laminin N terminus α31 (LaNt α31) has widespread
expression in human tissues (Troughton et al., 2020b), is
upregulated during wounding and corneal limbal stem cell
activation (Barrera et al., 2018) and emerging data indicate
that it can modulate LM organization in vitro (Troughton
et al., 2020a). In vivo overexpression is embryonic lethal during
development with tissue defects that resemble LM network
disruption phenotypes (Sugden et al., 2020).
From an evolutionary perspective, netrin-4, LaNt α31
and proteolytically released LN fragments represent multiple
mechanisms to fine-tune LM network assembly. Although
human diseases directly associated with loss-of-function
mutations have not been identified, a SNP in the netrin-4 gene
(causing Y205H) has been associated with late onset Alzheimer’s
disease (Saad et al., 2015), and dysregulation of expression
appear to contribute to tumor pathogenesis and point toward
an additional important aspect of BM biology (Schneiders et al.,
2007; Reuten et al., 2016, 2021; Troughton et al., 2020c).
Rescuing LN Domain Defects
Although the standard gene and protein therapy toolbox are
available to treat LN domain disorders, the large size of LM
genes and associated challenges of producing and delivering
recombinant therapy-grade LM protein presents challenges.
However, promising results have been obtained recently from
delivering the 800 kDa LM521 to the blood stream of LAMB2-
null mice which rescues some aspects of Pierson syndrome.
The delivered LM521 accumulated in the glomerular basement
membrane in the correct orientation and led to reduced
expression of the podocyte injury markers, and delayed the
onset of proteinuria. However, the exogenous LM521 did not
migrate to the podocytes nor fully restore the glomerular
filtration barrier. Smaller, or hybrid proteins, may be a solution
to overcome these challenges (Lin et al., 2018). For some LM
disorders, upregulating expression of a compensatory LM may
be a viable option. While there are differences, LMα1 and LMα2
are very similar both structurally and functionally, therefore in
LMα2-deficient MDC1A, increasing LMα1 could compensate
for the lack of functional LMα2. LMα1 expression is usually
downregulated following development; however, encouraging
progress has been made here using guide RNA to target the LMα1
promoter with inactive Cas9 coupled to VP160 transcription
activation domain. In mouse models, electroporation of the
gRNA-containing plasmids into the tibialis anterior of 4-week old
animals led to increased expression of LM111 with appropriate
localization 2-weeks post-electroporation (Perrin et al., 2017).
This data provides an encouraging base for development that may
be exploitable for other conditions using a similar approach.
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A particularly innovative solution exploiting the knowledge
gained from studying LM polymerization and counteracting
the inherent LM size problems is using protein chimeras to
act as linkers (McKee et al., 2009, 2017; Reinhard et al.,
2017). Three such “Frankenstein” chimeric proteins have been
created, a fusion of a functional LN domain to the LM binding
region of nidogen, a miniature form of agrin (mini-agrin)
containing only the LM-binding regions and α-dystroglycan
binding regions, and a fusion between LM-binding domains
of agrin and the dystroglycan binding domain of perlecan. As
LM411 is upregulated in MDC1A but cannot compensate for
LM211 dysfunction, the nidogen/LN domain chimeric protein
can be used to bind the γ1 chain of LM411 via the nidogen region
and provide the missing αLN domain needed to allow LM411
polymerization (Reinhard et al., 2017). The mini-agrin/perlecan
chimeras can be used in concert with the nidogen chimera to
compensate for α-dystroglycan binding (Talts et al., 2000; Moll
et al., 2001). Where patients harbor LN mutations, only the
nidogen fusion would be required, whereas for knockout both
the LN/nidogen and mini-agrin would be necessary. Promising
results have been observed with these chimeras in mouse
models. Moreover, switching the LN domain from an αLN to
βLN, this approach is likely to also be effective for Pierson
syndrome patients.
DISCUSSION AND PERSPECTIVES
Comparison between knockout and missense mutation
associated phenotypes in LM genes has provided valuable
information to identify which LMs are essential for individual
tissues, but also which domains are involved. Rather than a
binary outcome caused by ability or inability to polymerize, we
see system-wide differences highlighting the multifaceted roles of
LN domains. The variety of pathologies arising from mutations
within a stretch of ∼250 amino acids illustrate the importance of
LN domains to tissue function.
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